AWARD A LETTER CONTRACT FOR RADX TECH - OASIS DIAGNOSTICS TO COMPLETE THE VALIDATION, APPROVAL, AND PRODUCTION PROCESSES IN ORDER TO SCALE UP CAPACITY

$76.79M USD

Funder	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Recipient Organization	Oasis Diagnostics Corporation
Country	United States
Start Date	Jan 08, 2021
End Date	Jan 07, 2022
Duration	364 days
Number of Grantees	1
Roles	Principal Investigator
Data Source	NIH (US)
Grant ID	`10505989`

Grant Description

Oasis Diagnostics provides a series of innovative tools for standardized saliva acquisition including devices specific for cell free RNA / viral RNA that are ideally suited for COVID-19 testing on difficult saliva specimens.

These collection tools [Pureâ?¢SAL, Superâ?¢SALâ?¢, Microâ?¢SAL and SimplOFy] in particular are agnostic to the test being used and are already being used by many companies developing oral / saliva based tests for COVID-19.

Oasis is a small business with under 20 employees and has been requested by companies developing COVID-19 to scale up manufacturing in order to produce volumes in excess of 100,000 Units of these technologies on a daily basis.

In order to be able to meet this goal, Oasis Diagnostics requires additional manpower, equipment and additional resources that it does not have at the present time.

As a result Oasis is seeking funding through the RADx Program to facilitate large scale manufacturing to meet the rapidly growing market for saliva collection technologies